SCHEMBL2293756

SCHEMBL2293756

Cc1cc(F)cc(C)c1Nc1c(-c2ccccc2OCC(N)=O)nc2ccccn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.44
GAA P10253 10/20 0.44
SMN1; SMN2 Q16637 6/20 0.44
HTT P42858 2/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
TP53 P04637 7/20 0.42
THRB P10828 1/20 0.42
PKM P14618 1/20 0.40
PKLR P30613 1/20 0.40
KCNN4 O15554 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
LMNA P02545 1/20 0.38
GFER P55789 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292520 0.93 GAA (0.45) MAPTGAASMN1; SMN2HTTMAPK1
SCHEMBL2291110 0.91 TRPA1 (0.42) MAPTGAASMN1; SMN2TP53KCNN4
SCHEMBL2288504 0.91 GAA (0.54) MAPTGAASMN1; SMN2HTTMAPK1
SCHEMBL2288909 0.89 GAA (0.49) MAPTGAASMN1; SMN2HTTMAPK1
SCHEMBL2290324 0.89 GAA (0.49) MAPTGAASMN1; SMN2HTTMAPK1
SCHEMBL2296176 0.86 TRPA1 (0.41) MAPTGAASMN1; SMN2KMT2AL3MBTL1
SCHEMBL2295279 0.85 GAA (0.48) MAPTGAASMN1; SMN2HTTMAPK1
SCHEMBL2290892 0.85 GAA (0.49) MAPTGAASMN1; SMN2HTTMAPK1
SCHEMBL2287174 0.84 GAA (0.44) MAPTGAASMN1; SMN2HTTMAPK1
SCHEMBL2290139 0.84 GAA (0.41) MAPTGAASMN1; SMN2HTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 MAPT 1138/4885GAA 1202/4885SMN1; SMN2 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.